Peter J Tummino
Overview
Explore the profile of Peter J Tummino including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
3327
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wyce A, Matteo J, Foley S, Felitsky D, Rajapurkar S, Zhang X, et al.
Oncogenesis
. 2018 Apr;
7(4):35.
PMID: 29674704
BET inhibitors exhibit broad activity in cancer models, making predictive biomarkers challenging to define. Here we investigate the biomarkers of activity of the clinical BET inhibitor GSK525762 (I-BET; I-BET762) across...
2.
Dhanak D, Edwards J, Nguyen A, Tummino P
Cell Chem Biol
. 2017 Sep;
24(9):1148-1160.
PMID: 28938090
Advances in understanding the role and molecular mechanisms underlying immune surveillance and control of (pre)malignancies is revolutionizing clinical practice in the treatment of cancer. Presently, multiple biologic drugs targeting the...
3.
DesJarlais R, Tummino P
Biochemistry
. 2016 Jan;
55(11):1584-99.
PMID: 26745824
In 1964, Alfrey and colleagues proposed that acetylation and methylation of histones may regulate RNA synthesis and described "the possibility that relatively minor modifications of histone structure, taking place on...
4.
Mohammad H, Smitheman K, Kamat C, Soong D, Federowicz K, Van Aller G, et al.
Cancer Cell
. 2015 Jul;
28(1):57-69.
PMID: 26175415
Epigenetic dysregulation has emerged as an important mechanism in cancer. Alterations in epigenetic machinery have become a major focus for targeted therapies. The current report describes the discovery and biological...
5.
Ott H, Graves A, Pappalardi M, Huddleston M, Halsey W, Hughes A, et al.
Mol Cancer Ther
. 2014 Sep;
13(12):3062-73.
PMID: 25253781
The EZH2 methyltransferase silences gene expression through methylation of histone H3 on lysine 27 (H3K27). Recently, EZH2 mutations have been reported at Y641, A677, and A687 in non-Hodgkin lymphoma. Although...
6.
Gallagher S, Mijatov B, Gunatilake D, Gowrishankar K, Tiffen J, James W, et al.
Pigment Cell Melanoma Res
. 2014 Jun;
27(6):1126-37.
PMID: 24924589
The transcription factor NF-kappaB (NF-kB) is a key regulator of cytokine and chemokine production in melanoma and is responsible for symptoms such as anorexia, fatigue, and weight loss. In addition,...
7.
Verma S, Tian X, LaFrance L, Duquenne C, Suarez D, Newlander K, et al.
ACS Med Chem Lett
. 2014 Jun;
3(12):1091-6.
PMID: 24900432
The histone H3-lysine 27 (H3K27) methyltransferase EZH2 plays a critical role in regulating gene expression, and its aberrant activity is linked to the onset and progression of cancer. As part...
8.
Knight S, Adams N, Burgess J, Chaudhari A, Darcy M, Donatelli C, et al.
ACS Med Chem Lett
. 2014 Jun;
1(1):39-43.
PMID: 24900173
Phosphoinositide 3-kinase α (PI3Kα) is a critical regulator of cell growth and transformation, and its signaling pathway is the most commonly mutated pathway in human cancers. The mammalian target of...
9.
Mazur P, Reynoird N, Khatri P, Jansen P, Wilkinson A, Liu S, et al.
Nature
. 2014 May;
510(7504):283-7.
PMID: 24847881
Deregulation of lysine methylation signalling has emerged as a common aetiological factor in cancer pathogenesis, with inhibitors of several histone lysine methyltransferases (KMTs) being developed as chemotherapeutics. The largely cytoplasmic...
10.
Campbell R, Tummino P
J Clin Invest
. 2014 Jan;
124(1):64-9.
PMID: 24382391
Over the past several years, there has been rapidly expanding evidence of epigenetic dysregulation in cancer, in which histone and DNA modification play a critical role in tumor growth and...